Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mapping Real-world Rebiopsy Events to Treatment Trajectories in EGFR/ALK/ROS1-Driven Non-small-cell Lung Cancer: Insights from the AURORA Cohort.

Clinical lung cancer - 1 May 2026

Williams C, Rogers J, Arasaratnam D, Pham T, Nguyen A, Rashed L, Tadesse F, Truong A, Zhang H, Selbie L, Geng J, Tan L, Harden S, Solomon B J, Alexander M

Abstract excerpt

BACKGROUND: Rebiopsy to identify resistance mechanisms and guide individualised treatment plans for systemic therapy is emerging as a fundamental practice in the management of oncogene-driven non-small cell lung cancer (NSCLC). The application of rebiopsy in real-world practice remains incompletely characterised. PATIENTS AND METHODS: This retrospective cohort study included patients with EGFR-, ALK-, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Biopsy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Follow-Up Studies

Share to Lung Neoplasms

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins

Source

Identifiers

PMID: 42014297
DOI: 10.1016/j.cllc.2026.03.007

Genes

ALK
EGFR
ROS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mapping Real-world Rebiopsy Events to Treatment Trajectories in EGFR/ALK/ROS1-Driven Non-small-cell Lung Cancer: Insights from the AURORA Cohort.PMID 42014297Read ↗

Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications.Semantic proximity Read ↗

Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: A single-center retrospective study.Semantic proximity Read ↗

The BREATHE project: An observational prospective cohort integrating clinical data, blood samples and tumor tissue from newly diagnosed patients with lung cancerSemantic proximity Read ↗

Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx StudySemantic proximity Read ↗

Implementing Genomic Testing for Lung Cancer Into Routine Clinical Practice - The Welsh Experience.Semantic proximity Read ↗

Repeated rebiopsy for detection of EGFR T790M mutation in patients with advanced-stage lung adenocarcinoma: Associated factors and treatment outcomes of Osimertinib.Semantic proximity Read ↗

Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network.Semantic proximity Read ↗

Usefulness of bronchial washing fluid for detection of EGFR mutations in non-small cell lung cancer.Semantic proximity Read ↗

Lung cancer treated abroad with receptor tyrosine kinase inhibitor.Semantic proximity Read ↗

Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01).Semantic proximity Read ↗

Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibitionSemantic proximity Read ↗

[New biopsy at lung cancer progression: rational treatment of resistant lung cancer].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.